Stay updated on Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.

Latest updates to the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%
- Check23 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, changing the page's revision label.SummaryDifference0.1%
- Check37 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%
- Check44 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check51 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new information on pathological conditions and specific drugs like pembrolizumab and idelalisib. Notably, previous content related to certain locations and various medical topics has been removed.SummaryDifference4%
- Check65 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Idelalisib in Lung Cancer Clinical Trial page.